05/27/2026 06:00
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 2026

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611i EudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs...

05/18/2026 16:10
Belkin Advances Towards Carbon Neutrality in Scope 3 Emissions

Belkin, a leading consumer electronics brand for 40 years, published its 2025 Impact Report, highlighting key achievements and reaffirming its commitment to corporate responsibility. Having achieved carbon neutrality in scope 1 and scope 2 emissions in 2025, the company continues to advance toward scope 3 carbon neutrality through enhanced life cycle assessment capabilities and improved supplier and logistics data collection. In 2025, Belkin calculated 131 product carbon footprints across its p...

06/16/2026 10:00
Aurora Solar Adds Integrated Storage Modeling to HelioScope, Uniting Commercial Solar Design, Storage, and Financial Analysis in One Solution

Aurora Solar, the leading global platform for solar sales and design, today announced the addition of integrated storage modeling to HelioScope. This new feature empowers users to size storage, model performance, and run the financial case in the same place they design the system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616352623/en/A preview of how storage modeling is integrated into the design workflow in HelioScope for ...

05/27/2026 06:49
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)

Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal respon...

06/16/2026 11:21
XBOW Named Winner in Fast Company’s 2026 World Changing Ideas Awards

XBOW, the leader in autonomous offensive security, today announced it has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, recognizing bold, transformative efforts that solve the world’s most pressing issues through creativity, technology, and measurable impact. As AI transforms every industry, it is also reshaping the threat landscape. AI-powered attackers can operate continuously, scale instantly, and uncover vulnerabilities faster than traditional security teams can ...

06/16/2026 11:01
Lenovo Tab Plus Gen 2 Delivers a Smarter, More Immersive Entertainment Experience

Today Lenovo™ introduced the Tab Plus Gen 2, the next generation of its tablet created for the increasingly fluid ways people move between media consumption, multitasking, and shared experiences. With upgrades spanning audio, visuals, versatility, and intelligent features, it expands the role of the tablet across a broader range of activities and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616736263/en/ “Entertai...

06/16/2026 11:30
G+D Launches AI Hub in Montréal to Advance Secure AI for Critical Infrastructure

Global SecurityTech company Giesecke+Devrient (G+D) today announced the launch of its AI Hub in Montréal. Located at Mila, the hub is at the heart of G+D’s Global Center of Excellence for AI. It will develop AI solutions for security-critical environments, including authentication, cybersecurity for digital infrastructures, secure payment and transaction AI, and group-wide internal AI projects — where security, privacy and regulatory compliance are paramount. G+D has invested approximately 40...